Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cocrystal Pharma, Inc. (COCP) announced the appointment of Fred Hassan to its Board of Directors, expanding the board to six members. Hassan brings over 40 years of experience in the pharmaceutical industry, having held senior roles at major companies and investment firms. His recent $2 million investment in Cocrystal via an at-the-market private placement underscores his confidence in the company's prospects.
The Chairman of the Board, Roger Kornberg, expressed optimism that Hassan's expertise will strengthen corporate governance and help advance Cocrystal's antiviral pipeline. Hassan emphasized the company's potential to develop innovative antiviral therapies using a unique structure-based discovery platform. This announcement signals a strategic move for Cocrystal as it aims to enhance its leadership and drive its research efforts towards commercialization.
Cocrystal Pharma (Nasdaq: COCP) announces the acceptance of an oral presentation of new data from its CC-42344 Phase 1 influenza A study at the 7th Annual ISIRV Antiviral Group Conference on May 4, 2023. Dr. Sam Lee, President and co-CEO, will present insights on the first-in-human study of CC-42344, a novel broad-spectrum influenza A polymerase PB2 inhibitor. The company anticipates filing for regulatory approval for a Phase 2a human challenge study later in 2023. CC-42344 has shown potent antiviral activity against various influenza A strains, including those resistant to existing treatments like Tamiflu and Xofluza.
This presentation aligns with the conference theme, “Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19.” Cocrystal plans to summarize the data presented and share slides on its website after the conference.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a private placement of 2,030,458 shares of common stock at $1.97 per share, raising $4.0 million. The investment was made by notable industry leaders Phillip Frost, M.D., and Fred Hassan, each contributing $2.0 million. This capital infusion strengthens Cocrystal's financial position as it prepares for significant clinical milestones. The company is set to commence a Phase 2a human challenge study for its PB2 inhibitor CC-42344 and a first-in-human trial for its COVID-19 protease inhibitor CDI-988, both pending regulatory approvals. Additionally, a lead candidate in the norovirus program is expected to be selected by mid-2023.
Cocrystal Pharma, Inc. (Nasdaq: COCP) reported financial results for the year ending December 31, 2022, revealing a net loss of $38.8 million, or $4.77 per share, up from $14.2 million, or $0.16 per share in 2021. R&D expenses increased to $12.4 million as the company advanced its antiviral pipeline, including the CC-42344 Phase 1 trial and upcoming CDI-988 Phase 1 trial. Cocrystal plans to submit UK and Australian regulatory filings for influenza and COVID-19 studies, respectively. The company reported unrestricted cash of $37.1 million as of December 31, 2022, with working capital at $39 million.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that CFO and co-CEO James Martin will present at the Virtual Investor Summit Conference on March 29, 2023, at 10:30 a.m. Eastern time. The presentation will highlight significant advancements and upcoming milestones in their antiviral programs targeting influenza A, COVID-19, and norovirus. The company employs innovative structure-based technologies to develop novel antiviral therapeutics aimed at viral replication processes.
For more details, interested parties can register for the presentation online.